Asset Details
Do you wish to reserve the book?
ABSTRACT NUMBER: ESOC2026A646 DRUG-ELUTING VERSUS BARE-METAL BALLOON-MOUNTED STENT FOR ACUTE INTRACRANIAL STENTINGS: INSIGHTS FROM THE RESISTANT REGISTRY
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
ABSTRACT NUMBER: ESOC2026A646 DRUG-ELUTING VERSUS BARE-METAL BALLOON-MOUNTED STENT FOR ACUTE INTRACRANIAL STENTINGS: INSIGHTS FROM THE RESISTANT REGISTRY
Do you wish to request the book?
ABSTRACT NUMBER: ESOC2026A646 DRUG-ELUTING VERSUS BARE-METAL BALLOON-MOUNTED STENT FOR ACUTE INTRACRANIAL STENTINGS: INSIGHTS FROM THE RESISTANT REGISTRY
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
ABSTRACT NUMBER: ESOC2026A646 DRUG-ELUTING VERSUS BARE-METAL BALLOON-MOUNTED STENT FOR ACUTE INTRACRANIAL STENTINGS: INSIGHTS FROM THE RESISTANT REGISTRY
2026
Overview
Abstract
Background and aims
Rescue intracranial stenting is increasingly used in patients with large vessel occlusion (LVO) when reperfusion fails or when severe stenosis is present. This study aimed to evaluate the influence of drug-eluting technology on clinical and radiological outcomes from the RESISTANT registry.
Methods
The RESISTANT registry is a multicenter and international which includes patients who underwent intracranial stenting during endovascular treatment for acute ischemic stroke (2016–2023). The primary endpoint was good functional outcome at 90 days (mRS 0–2). Secondary endpoints included successful reperfusion (eTICI 2b–3), 24-hour stent patency, complications, and in-hospital mortality. Outcomes were compared between drug-eluting (DE) and bare-metal (BM) balloon-mounted stents.
Results
Among the balloon-mounted stents, 97 (55.1%) were DE and 79 (44.9%) were BM. Baseline clinical and radiological characteristics were similar between groups.
During the procedure, the number of thrombectomy attempts (1.0 (0.0-2.0) vs 2.0 (1.0-3.0), p=0.008) were lower in BM group. Moreover, pre-stenting successful recanalization was higher in BM group (56.6% vs 31.5%, p=0.004). Finally, procedural antiplatelet treatment differed between groups with a higher rate of double antiplatelet therapy in DE group (BM 35.4% vs DE 68.0%, p<0.001).
No differences were found at procedural or 90 days clinical outcomes. Symptomatic intracranial hemorrhage was more frequent in DE group (13.4% vs 3.1%, p=0.026) without a significant association (aOR (95%CI) 2.446 (0.214 - 27.989); p=0.472).
Conclusions
In our cohort, the use of DE technology was not a predictor of clinical outcome. Symptomatic intracranial hemorrhage was more frequent in DE group probably related to a more aggressive antiplatelet strategy.
Conflict of interest
All authors: nothing to disclose.
Publisher
Oxford University Press
Subject
